Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
News
$ 8.16
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease;...
Target Price
The average target price of RGLS is 9.4 and suggests 15% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation s
Data is available to registered users only
